Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K.

Mod Rheumatol. 2010 Feb;20(1):40-5. doi: 10.1007/s10165-009-0235-4. Epub 2009 Oct 3.

PMID:
19802651
2.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
3.

Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.

Hayashi M, Kojima T, Funahashi K, Kato D, Matsubara H, Shioura T, Kanayama Y, Hirano Y, Ishiguro N.

Mod Rheumatol. 2012 Jun;22(3):363-9. doi: 10.1007/s10165-011-0527-3. Epub 2011 Oct 7.

PMID:
21979824
4.

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR; Research in Active Rheumatoid Arthritis (ReAct) Study Group.

Rheumatology (Oxford). 2007 Jul;46(7):1191-9. Epub 2007 May 15.

PMID:
17504821
5.
6.

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.

Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM; CORRONA Investigators.

Ann Rheum Dis. 2012 Jul;71(7):1134-42. doi: 10.1136/annrheumdis-2011-150573. Epub 2012 Jan 30.

PMID:
22294625
7.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
8.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark.

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

9.

Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.

Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8. Epub 2012 Mar 6.

PMID:
22153557
10.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
11.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.

PMID:
25231180
12.

Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.

Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.

J Rheumatol. 2014 Dec;41(12):2352-60. doi: 10.3899/jrheum.131299. Epub 2014 Oct 1.

PMID:
25274894
13.

Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.

J Rheumatol. 2011 Nov;38(11):2346-54. doi: 10.3899/jrheum.101295. Epub 2011 Oct 1.

PMID:
21965648
15.

Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.

Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.

J Clin Rheumatol. 2012 Jun;18(4):180-4. doi: 10.1097/RHU.0b013e31825828be.

PMID:
22647860
16.

Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Naredo E, Möller I, Cruz A, Carmona L, Garrido J.

Arthritis Rheum. 2008 Aug;58(8):2248-56. doi: 10.1002/art.23682.

17.

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.

Van Doornum S, McColl G, Wicks IP.

Rheumatology (Oxford). 2005 Nov;44(11):1428-32. Epub 2005 Aug 2.

PMID:
16076882
18.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
19.

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.

Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D.

Curr Med Res Opin. 2014 Nov;30(11):2139-49. doi: 10.1185/03007995.2014.942416. Epub 2014 Jul 30.

PMID:
25050591
20.

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians.

Ann Rheum Dis. 2006 Jun;65(6):746-52. Epub 2005 Dec 8.

Supplemental Content

Support Center